NCT06475326View on ClinicalTrials.gov

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

Adebrelimab

Adebrelimab ,20mg/Kg per time, Q4W

DRUG

Oxaliplatin 100 MG

Oxaliplatin: 60mg/m2, Q2W

DRUG

Irinotecan liposome

Irinotecan Liposome: 50mg/m2, Q2W

DRUG

Calcium Folinate

Calcium Folinate: 400mg/m2, Q2W

DRUG

Fluorouracil

Fluorouracil: 2400mg/m2, Q2W

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER